Endocrine dynamic tests are diagnostic procedures in which a hormonal axis is assessed during a controlled perturbation, induced either by a stimulus or by suppression, to measure the system’s ability to generate an adequate response over time. In endocrinology, a simple basal measurement is often insufficient because many secretions are pulsatile, follow circadian rhythms or depend on the physiological context; moreover, an “instantaneous” concentration may be normal despite reduced functional reserve, or altered by non-pathological factors. Dynamic tests therefore occupy the area where physiology becomes clinical practice: they interrogate the robustness of homeostasis and transform a numerical value into an interpretable temporal trajectory.
Conceptually, every dynamic test measures three elements: the integrity of the source, whether a gland or hypothalamic neurons, the effectiveness of regulatory circuits, namely feedback and feedforward, and the sensitivity of target tissues or “effector organs” participating in the response. The result is not a single isolated cut-off but a pattern, defined by latency, amplitude, duration and return to baseline. This framework is crucial to avoid a common error: interpreting a dynamic test as an “enhanced laboratory test”, whereas it is actually a clinically standardized physiological experiment.
In practice, dynamic tests are used mainly when the stakes are high and basal uncertainty is relevant: suspected adrenal insufficiency, mild or subclinical hypercortisolism, disorders of growth hormone (GH) secretion, polyuria-polydipsia syndromes, primary aldosteronism, pheochromocytoma/paraganglioma with borderline screening results, endogenous hypoglycemia, and selected forms of hypogonadism or abnormal puberty. Every test also carries a potential risk because it deliberately induces a non-physiological state. For this reason, test selection, execution and interpretation must follow a rigorous method, with a clear diagnostic hierarchy and constant attention to factors that can produce false positives and false negatives.
A dynamic test starts from a pathophysiological hypothesis. If a deficit, or insufficiency, is suspected, the objective is to demonstrate that a reserve cannot be activated when required; if an excess, or autonomous hypersecretion, is suspected, the objective is to demonstrate that a physiological brake fails to suppress production. This leads to a fundamental distinction: stimulation tests and suppression tests. The former carry a risk of false negatives if the stimulus is too weak or the observation period is insufficient; the latter carry a risk of false positives if suppression is incomplete because of absorption, metabolism, drug interactions or biological variability in the response.
The choice of dynamic test should not be made “from a catalogue”, but guided by three clinical criteria: pre-test probability, consequences of the decision, and test performance in the specific population. In a setting with high pre-test probability and high clinical risk, tests with high sensitivity are preferred and, if necessary, lower specificity is accepted provided that a second step is used for confirmation. In a low pre-test probability setting, indiscriminate use of dynamic tests increases false positives and generates a diagnostic cascade, with possible iatrogenic harm. The correct logic is stratification: targeted screening, confirmation with an appropriate dynamic test, then etiological definition with imaging or invasive procedures only when indicated.
An often underestimated principle is the dependence of the test on its “context”. Age, sex, nutritional status, pregnancy, liver and kidney function, critical comorbidities and medications can modify results. For example, in cortisol tests, circadian rhythm, stress and inflammatory status influence the response; in GH tests, obesity attenuates peaks and increases the risk of overdiagnosis; in polyuria testing, arginine vasopressin regulation is sensitive to osmolality and anxiety, with fluctuations that may mimic disease. To be interpretable, a dynamic test must therefore be embedded in a coherent clinical framework and performed with rigorous standardization.
Finally, the hierarchy of dynamic tests must respect the concept of “first-line test” and “alternative test”. Some tests are regarded as historical or physiological references, but may be contraindicated or impracticable. The insulin tolerance test is a paradigmatic example: it is highly informative for GH and adrenocorticotropic hormone (ACTH), but it induces hypoglycemia and is not suitable for everyone. Modern endocrinology therefore uses a strategy of clinical equivalence: selecting a validated alternative test, with cut-offs specific to the method and population, and interpreting it together with clinical findings and other biomarkers, while avoiding the transfer of thresholds from one test to another.
The quality of a dynamic test depends on preparation that begins before blood sampling. Standardization includes timing, fasting, posture, rest, environment, reliable venous access and the temporal sampling plan. Timing is especially important for the hypothalamic-pituitary-adrenal axis: cortisol and ACTH have a morning peak and an evening decline, so a test performed at inappropriate times may produce results that are difficult to compare with cut-offs. Fasting is critical for tests involving insulin and counterregulation; even a “poorly defined” fasting period can alter responses to glucagon or hypoglycemia. Posture influences renin and aldosterone; the simple difference between recumbency and standing modifies activity of the renin-angiotensin-aldosterone system and may alter the interpretation of confirmatory tests or basal profiles used to select the dynamic test.
Safety assessment must precede the test. Absolute and relative contraindications must be identified, with particular attention to tests that induce hypoglycemia or electrolyte disturbances. The insulin tolerance test is contraindicated in significant ischemic heart disease, uncontrolled arrhythmias, epilepsy, severe frailty and conditions that make hypoglycemia hazardous. Tests with hypertonic saline or water deprivation require monitoring of sodium and neurological signs, because rapid correction or hypernatremia can cause complications. Dexamethasone suppression tests can be influenced by drugs that modify dexamethasone metabolism and can generate erroneous interpretations if adherence is not checked or if clinical interferences such as alcohol use, major depression or severe stress, which may alter the hypothalamic-pituitary-adrenal (HPA) axis, are not recognized.
Intra-test management must be proactive. For tests lasting several hours, an operational checklist is useful: vital signs, expected symptoms, stopping thresholds, correctly labelled samples and recorded sampling times. In hypoglycemia tests, the threshold is not only numerical: the presence of neuroglycopenic symptoms and the ability to obtain samples within critical time windows are decisive. In polyuria-polydipsia tests, quality depends on repeated monitoring of weight, osmolality and sodium, with rapid decisions to avoid excessive dehydration or hypernatremia. A test performed without a safety protocol often produces ambiguous data and, paradoxically, increases risk exposure because it forces repetition or subsequent procedures.
Another safety element is awareness of “non-testable conditions”. In severe acute illness, the immediate postoperative period, intensive care admissions or major inflammatory states, many endocrine axes are adaptively altered. In these contexts, a dynamic test may measure a physiological stress response rather than a primary disease. The decision to postpone testing, or to use more robust alternative criteria, is often part of endocrinological competence and reduces spurious diagnoses.
Dynamic assessment of the HPA axis requires a clear distinction between adrenal insufficiency and hypercortisolism, because the tests and rationales are opposite. In adrenal insufficiency, the clinical question is whether cortisol production can increase adequately under stress conditions; in hypercortisolism, the question is whether secretion is suppressible and therefore still under physiological control. In addition, the same cortisol concentration may have different meanings depending on the analytical method and the concentration of cortisol-binding globulin (CBG); this requires caution when applying “historical” cut-offs without considering the laboratory context.
For primary adrenal insufficiency, a practical reference is the stimulation test with synthetic ACTH, or cosyntropin, which assesses the ability of the adrenal cortex to produce cortisol after stimulation. The standard test uses a conventional dose and measurements at defined time points; interpretation must take into account time of day, basal values and the time elapsed since any adrenal injury. A known pathophysiological limitation is that in the early stages of secondary or tertiary insufficiency, the adrenal gland may still be relatively responsive to exogenous ACTH, whereas endogenous secretion is insufficient. In these cases, a test based on insulin-induced hypoglycemia or other central stimuli may be more sensitive, but carries greater risk and requires dedicated expertise. A modern and pragmatic choice is to use an algorithm: targeted basal evaluation, ACTH testing as the first step in most cases, and alternative tests in contexts where the diagnosis remains uncertain and the clinical impact is high.
When hypercortisolism is suspected, first-line tests are typically based on suppression or integrated measurement, because cortisol secretion has a circadian rhythm and intraindividual variability that make a single basal measurement unreliable. Low-dose dexamethasone suppression is a cornerstone test: it measures the ability of glucocorticoid feedback to reduce endogenous production. Interpretation requires attention to drugs that induce or inhibit dexamethasone metabolism and to conditions that may alter cortisol dynamics. In contemporary practice, this assessment is also essential in the management of adrenal incidental masses, where the aim is to identify a mild form of autonomous secretion that may not produce the classic Cushingoid phenotype but may increase cardiometabolic risk.
When the picture is equivocal, confirmation strategies and tests that increase specificity are used, such as combined protocols or repeated testing with coherent methods. It is important to understand that hypercortisolism may be intermittent or cyclic and that acute stress can produce “pseudo-Cushing” states that mimic some patterns. In these cases, consistency among clinical findings, integrated biomarkers and repetition under stabilized conditions is often more informative than a single test pushed to the extreme. Clinical competence consists in balancing sensitivity and specificity, avoiding both diagnostic delay in genuine forms and pathological labelling of adaptive states.
GH is the paradigmatic hormone for which basal assessment is often useless: secretion is pulsatile and influenced by sleep, physical activity, stress, caloric intake, estrogens and body composition. For this reason, endocrinology uses two complementary strategies: insulin-like growth factor 1 (IGF-1) as an integrated marker of GH exposure and dynamic tests as functional evidence when IGF-1 is uncertain or when diagnosis requires confirmation in particular contexts. However, IGF-1 also has biological and analytical dependencies, so cut-offs must be referred to age- and sex-specific ranges, ideally using the same method during follow-up.
In acromegaly, the classic dynamic test is GH suppression after an oral glucose load. The rationale is physiological: hyperglycemia suppresses GH in normal subjects; failure of suppression suggests autonomous secretion or secretion uncoupled from metabolic control. Interpretation must consider that the suppression threshold depends on the GH assay method and that conditions such as uncontrolled diabetes or acute illness may alter the curve. Contemporary literature tends to emphasize the centrality of IGF-1 for diagnosis in the presence of a typical phenotype and uses the glucose test mainly in equivocal or discordant cases, where a dynamic element is needed to resolve the conflict between clinical findings and biomarkers.
In adult GH deficiency, diagnosis almost always requires a stimulation test because a “low” basal GH is physiological during many hours of the day. The physiological reference test is the insulin tolerance test, which stimulates GH through hypoglycemia and counterregulatory activation; however, its risk profile has favored the use of alternatives. The glucagon stimulation test is one of the most commonly used alternatives because it avoids profound hypoglycemia, while still requiring careful monitoring for nausea, delayed hypoglycemia and response variability. In recent years, the introduction of macimorelin, an oral GH secretagogue stimulus, has provided a simpler and better tolerated option in selected contexts, with dedicated cut-offs. In all cases, a crucial principle is that cut-offs are not universal: they must be specific to the test, method and often to body mass index (BMI), because obesity reduces GH peaks and can generate false positives if non-adjusted thresholds are applied.
The choice of test in GH deficiency is not only technical but clinical. In a patient with multiple pituitary hormone deficiencies and a compatible history, pre-test probability is high and a less risky test may be sufficient; in a patient with a borderline picture or controversial therapeutic indication, greater rigor is required, often with a highly accurate test or repetition. The diagnosis of GH deficiency is an example of “systems” endocrinology: it requires integration of history, including pituitary surgery, radiotherapy, trauma and tumors, clinical signs, IGF-1, the dynamic test and the metabolic context, while avoiding shortcuts that reduce a complex axis to a single numerical threshold.
The polyuria-polydipsia syndrome is an area in which dynamic diagnostics are often decisive. The clinical problem is not only confirming polyuria but distinguishing its etiology: vasopressin deficiency, now often conceptualized as arginine vasopressin deficiency, arginine vasopressin resistance and primary polydipsia. These conditions can produce overlapping clinical pictures and even overlapping basal parameters, especially if the patient has modified water intake as an adaptive behavior. In addition, urine osmolality can vary widely and may be influenced by solutes, diet and drugs. For this reason, dynamic assessment aims to stress the osmotic system in a controlled manner and measure the hormonal response or its surrogates.
The water deprivation test was long considered a reference: by reducing water intake, plasma osmolality rises, which should stimulate vasopressin secretion and urinary concentration. However, its accuracy is imperfect because the response is gradual and depends on behavioral variables, duration and the safety of the protocol. Moreover, in patients with chronic primary polydipsia, osmosensitivity may be “reset” and renal concentrating capacity may be reduced because of medullary gradient washout, producing intermediate results that complicate interpretation.
In recent years, the use of copeptin has become consolidated as a measurable surrogate for vasopressin, because it is released in an equimolar ratio but is more stable and technically easier to assay. This has enabled renewed use of more “direct” tests, based on measurement of the hormonal response during controlled osmotic stimulation, often by hypertonic saline infusion with close sodium monitoring. The copeptin-based approach allows, in many cases, more accurate distinction between central deficiency and primary polydipsia than water deprivation alone, although it requires an organized setting and rigorous safety protocols. Before any test, it remains essential to demonstrate the presence of hypotonic polyuria and to exclude common and reversible causes such as hyperglycemia and osmotic diuresis.
A key clinical element is that dynamic diagnostics in polyuria do not end with the label. Once the category has been defined, the cause must be sought, especially in central forms, through history, including trauma, surgery, neoplasms and infiltrative diseases, and hypothalamic-pituitary imaging when indicated. In this context, the dynamic test is the bridge between physiology and the etiological pathway, and its accuracy determines treatment safety, because incorrect therapy can be dangerous.
In endocrine hypertension, dynamic diagnostics play a role mainly in the confirmation phase, after selective biochemical screening. Primary aldosteronism is a classic example: after suspicion based on the aldosterone-renin ratio and the clinical picture, tests are used to assess aldosterone suppressibility when the renin-angiotensin system is reduced or when volume is expanded. The rationale is to distinguish appropriate aldosterone secretion, which switches off when volume increases, from autonomous secretion that remains inappropriately elevated. Confirmatory tests include saline loading protocols, the captopril test and, in selected centers, more intensive protocols. Here, standardization is critical: posture, dietary sodium, potassium, antihypertensive drugs and renal function influence results. A dynamic test performed without controlling these elements can produce an incorrect diagnosis, with relevant consequences because the subsequent pathway may include invasive procedures such as adrenal venous sampling.
For pheochromocytoma and paraganglioma, dynamic diagnostics are less central than sensitive measurements of metanephrines, but there are contexts in which suppression or functional confirmation may be useful, especially in borderline results or situations with high risk of false positivity. Adrenergic hyperactivation caused by stress, drugs or acute conditions can increase catecholamines and metabolites. In these cases, the correct choice is often to repeat testing under optimal conditions, review medications and reserve dynamic tests or more complex measures for cases in which pre-test probability remains significant. Here too, the rule is to avoid “aggressive diagnostics” in low pre-test probability scenarios, because the consequences of an incorrect diagnosis include repeated imaging and procedures with non-negligible risks.
A cross-cutting principle in endocrine hypertension is that dynamic tests do not replace clinical phenotyping. Signs of hypokalemia, family history, age at onset, presence of incidentalomas, treatment resistance and comorbidities guide which axis should be investigated and with what intensity. The dynamic test is a confirmatory element within a reasoned pathway, not a “universal” examination for every hypertensive patient.
Hypoglycemia in subjects not treated with glucose-lowering drugs is a diagnostic problem in which dynamics often coincide with pathophysiology. The first rule is to document the clinical and biochemical triad rigorously, because many subjective sensations can simulate hypoglycemia without a true glucose reduction. When endogenous hypoglycemia is suspected, the concept of a dynamic test takes the form of a controlled “provocative” test, often involving prolonged fasting in a monitored setting. The rationale is to reproduce the condition safely and simultaneously collect glucose, insulin, C-peptide, proinsulin and other markers useful for distinguishing causes. Standardization is decisive here: diagnosis depends on a coherent set of measurements taken at the same moment as the episode and on correct sample handling.
In other metabolic areas, selected dynamic tests may be useful in specific contexts, but they must be chosen judiciously to avoid unnecessary overlap with the page dedicated to biological variability and interferences. One example is assessment of glucose tolerance in particular conditions, or response tests to pharmacological stimuli in specialist settings. The key point is that, in endocrinology, many metabolic “abnormalities” are not primary endocrine diseases and a dynamic test can become misleading if the clinical question is not defined first.
The general lesson from hypoglycemia can be applied to all dynamic diagnostics: data quality depends on observing the phenomenon at the correct moment. A well-performed dynamic test reduces ambiguity because it captures the causal relationship between stimulus and response; a poorly performed test produces numbers that appear precise but do not answer the clinical question.